Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITCA 650 vs Empagliflozin and Glimepiride in T2D
NCT03060980Phase 3Terminated
- Sponsor
- Intarcia Therapeutics
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Peptides, Device-based Delivery
- Countries
- 2
01
Overview
A Phase 3 trial of ITCA 650 in type 2 diabetes mellitus (T2DM), sponsored by Intarcia Therapeutics. Started Mar 2017; status: terminated.
02
Drugs
ITCA 650
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03060980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03060980.